Cellulite

Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX

Retrieved on: 
Monday, April 8, 2024
Venus, Magnetic field, Communication, System, Spasm, Abdomen, History, Research, Human, Ministry of Health, Cellulite, Lipolysis, Annual report, Pain, Ministry, FDA

TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.

Key Points: 
  • TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.
  • The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions.
  • The Venus Bliss MAX offers three advanced technologies in one platform: diode laser applicators, (MP)2 applicator that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse™ technology and the Company’s FlexMax EMS applicators.
  • “The Venus Bliss MAX has been well received internationally, and we look forward to bringing our comprehensive all-in-one platform to the Israeli aesthetic service providers,” said Dr. Hemanth Varghese, President and Chief Operating Officer of Venus Concept.

NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year

Retrieved on: 
Monday, April 1, 2024
Research, Growth, JV, Amazon, Health, Partnership, International, Webcast, ABBV, Foot, Acquisition, Cellulite, OTC, Marketing, Advertising, Stada Arzneimittel, Video game

Adam Levy, NEXGEL’s Chief Executive Officer, commented, “2023 was a record year for NEXGEL and transformational in many respects.

Key Points: 
  • Adam Levy, NEXGEL’s Chief Executive Officer, commented, “2023 was a record year for NEXGEL and transformational in many respects.
  • Our nearly 100% year-over-year revenue growth in 2023 was primarily driven by our branded products and contract manufacturing.
  • The increase in revenue was primarily due to sales growth in contract manufacturing of 166% and an increase in branded product revenue by approximately $427,000, or 52.4%, to $1.24 million.
  • For the fourth quarter of 2023, branded products revenue was $392,000, an increase of 104.2% year-over-year and 10.1% sequentially.

Autonomix Appoints Jennifer Cook as Chief Business Officer

Retrieved on: 
Tuesday, March 19, 2024
AbbVie, Growth, Health, Miami University, Real Chemistry, Nervous system, Business administration, Integration, Adjustable gastric band, Research, Class, Marketing communications, Jennifer Cook, Electrophysiology, Record, Translation, Marketing, Cellulite, Advertising, AMIX, Management

THE WOODLANDS, TX, March 19, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the appointment of Jennifer Cook as its Chief Business Officer.

Key Points: 
  • Mrs. Cook is an innovative, cross-functional leader with significant expertise working with early developmental stage companies and building them into fully integrated companies.
  • “We are very pleased to welcome Jennifer to the Autonomix team.
  • Her expertise in business strategy and analysis will be of great value as we continue to execute on our corporate and clinical efforts moving forward.
  • Mrs. Cook holds a Bachelor of Science in Business Administration and Marketing from Miami University, Oxford, Ohio.

Global Medical Aesthetics Market, 2023-2035: Dominance of Minimally Invasive Procedures - North America Leads, Asia-Pacific Shows Promise - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Other Consumer, Medical Devices, Surgery, Women, LGBTQ+, Men, Consumer, Health, Cosmetics, Retail, Migraine, Type, Medical tourism, Elective surgery, COVID-19, Bariatric surgery, Hospital, Dermatology, IPL, Ageing, Breast, Cellulite, Safety, Market, Physician, FACE, Practitioner

The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.

Key Points: 
  • The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.
  • Presently, more than 200 medical aesthetics companies are engaged in offering various products and devices to fulfill aesthetic requirements of clients.
  • Additionally, medical aesthetic companies offer all types of invasive, non invasive and minimally invasive solutions to address the requirements of all end users, such as hospitals, medical aesthetic clinic and individuals in home care settings.
  • North America leads the medical aesthetics market, driven by advanced solutions, established companies, and high demand for cosmetic procedures.

Beverly Hills Non-Surgical Aesthetic Cosmetic Specialist, Sam Assassa, M.D., is Recognized as a 2024 Top Patient Rated Doctor

Retrieved on: 
Friday, March 1, 2024
Loyola University, Neck, Multimedia, Case Western Reserve University, Health, Patient, Cellulite, Nose, Face, Dentistry

BEVERLY HILLS, Calif., March 1, 2024 /PRNewswire/ -- Renowned cosmetic surgeon Dr. Sam Assassa, Director of Beverly Hills Aesthetics, has been recognized as a 2024 Top Patient Rated Doctor by Find Local Doctors. This prestigious award is a testament to Dr. Assassa's exceptional dedication to his patients and unwavering commitment to providing cutting-edge non-invasive cosmetic treatments. Passionate about delivering exceptional patient care, his expertise in non-surgical cosmetic procedures has made him a sought-after specialist in the industry. Dr. Assassa is proud to have performed more non-surgical facial and aesthetic procedures than any other cosmetic surgeon in Beverly Hills. His exceptional results and unwavering commitment to patient satisfaction have earned him recognition from both his patients and peers. At Beverly Hills Aesthetics, Dr. Assassa specializes in BOTOX DERMAL FILLERS AND cosmetic skin treatments for the face, neck and body. He employs the most advanced non-surgical and minimally invasive techniques to address a wide range of cosmetic concerns. Dr. Assassa is also known for his revolutionary treatments, including the EZ Lipo ™, a liposculpting technique performed under local anesthesia, SweatZap™, a procedure that permanently eliminates underarm sweat glands, Celluraze™, a non-surgical fat reduction and cellulite treatment, non-surgical fat transfer to the face, hands, and décolleté wrinkles and RINOFILL®, a non-surgical rhinoplasty that enhances the appearance of the nose without the risks associated with surgery. Dr. Assassa's innovative approach and dedication to staying at the forefront of the latest advancements in cosmetic surgery have made him a leader in the field.

Key Points: 
  • BEVERLY HILLS, Calif., March 1, 2024 /PRNewswire/ -- Renowned cosmetic surgeon Dr. Sam Assassa , Director of Beverly Hills Aesthetics, has been recognized as a 2024 Top Patient Rated Doctor by Find Local Doctors.
  • Passionate about delivering exceptional patient care, his expertise in non-surgical cosmetic procedures has made him a sought-after specialist in the industry.
  • Dr. Assassa is proud to have performed more non-surgical facial and aesthetic procedures than any other cosmetic surgeon in Beverly Hills.
  • At Beverly Hills Aesthetics, Dr. Assassa specializes in BOTOX DERMAL FILLERS AND cosmetic skin treatments for the face, neck and body.

Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS

Retrieved on: 
Friday, February 2, 2024
Research, Medical Devices, Clinical Trials, Biotechnology, Other Health, Health, General Health, Other Science, Science, Partnership, Extracellular matrix, Life, Patient satisfaction, Anatomy, Overalls, Patient, Skin, Human, Sculptra, Month, AIDS, Cellulite, Treatment, Assessment

Galderma, the emerging pure-play dermatology category leader, is proud to celebrate 25 years of Sculptra®, which enjoys the trust of healthcare professionals and unmatched patient satisfaction.

Key Points: 
  • Galderma, the emerging pure-play dermatology category leader, is proud to celebrate 25 years of Sculptra®, which enjoys the trust of healthcare professionals and unmatched patient satisfaction.
  • In partnership with leading aesthetic healthcare professionals, Galderma developed the AART™ (Anatomy, Assessment, Range and Treatment) methodology.
  • These treatments are built on patients’ underlying anatomy, a thorough facial assessment and product selection, combined with appropriate injection skills.
  • “Sculptra has a unique usage history in the aesthetic industry, one that has continually increased in synergy with our ongoing research.

Sirona Biochem Corporate Update January 2024

Retrieved on: 
Wednesday, January 24, 2024
IP, Cellulite, Communication, OTC, TSX, Allergan, Sirona, Safety, Intellectual property, SGLT, Ageing, Cosmeceutical, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update:

Key Points: 
  • VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) provides the following update:
    We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem's path forward.
  • Sirona Biochem will maintain majority ownership in the subsidiary.
  • Envisioning beyond a single product, Sirona Biochem sees a future of diversified offerings with multiple products utilizing GlycoProteMim.
  • By pursuing a quicker route to profitability, we reduce reliance on recurrent financing, ensuring stability and a sustainable growth trajectory for Sirona Biochem and its subsidiaries.

Sofwave Medical Receives 510(k) Marketing Clearance for Pure Impact™ Strength and Muscle Toning Body Module Utilizing PlyoPulse™ EMS Technology

Retrieved on: 
Wednesday, January 3, 2024
Food, FDA, EMS, Pure, SAN, Sofwave Medical, Cellulite, Skin, Medical device

The approval clears a pathway for Sofwave to expand medical aesthetic treatment beyond the Company’s existing SUPERB™ platform for eyebrow and submental neck lifting, treatment of fine lines and wrinkles, treatment of cellulite, and treatment of skin laxity to now allow practitioners to include body toning and strength conditioning across diverse muscle groups in one treatment session.

Key Points: 
  • The approval clears a pathway for Sofwave to expand medical aesthetic treatment beyond the Company’s existing SUPERB™ platform for eyebrow and submental neck lifting, treatment of fine lines and wrinkles, treatment of cellulite, and treatment of skin laxity to now allow practitioners to include body toning and strength conditioning across diverse muscle groups in one treatment session.
  • “We continue to deliver on our promise of innovation within the medical aesthetic device space.
  • The 510(k) clearance of Pure Impact™ allows Sofwave to bring to market a unique EMS device that can deliver muscle toning and strength conditioning simultaneously across diverse muscle groups in one treatment session,” noted, Louis Scafuri, CEO of Sofwave Medical.
  • “Pure Impact™ with PlyoPulse™ technology is a modular add-on to Sofwave’s existing industry-leading medical device platform, allowing practitioners to immediately expand their spa or clinics’ suite of services.

Sofwave Medical Receives FDA Clearance of SUPERB™ Technology For Improvement of the Appearance of Skin Laxity on the Upper Arm

Retrieved on: 
Tuesday, December 26, 2023
Food, FDA, Pain, Weight loss, Ageing, Trial of the century, Brachioplasty, SAN, Society, Plastic, Cellulite, Genetics, Acne, Chin, Skin, Medical device

Mr. Louis Scafuri, Sofwave CEO, commented: “We are pleased to receive FDA clearance for improvement of the appearance of skin laxity on the upper arms in the U.S. supported by compelling clinical study results.

Key Points: 
  • Mr. Louis Scafuri, Sofwave CEO, commented: “We are pleased to receive FDA clearance for improvement of the appearance of skin laxity on the upper arms in the U.S. supported by compelling clinical study results.
  • Lax skin on the upper arms is a prevalent issue that can impact individuals not only from a physical appearance aspect but also emotionally.
  • 93% of treated arms were “improved” or “very much improved” in appearance, as rated by the blinded reviewers using the Global Aesthetic Improvement Scale.
  • The Sofwave system is also cleared for short-term improvement in the appearance of cellulite and for the treatment of acne scars.

Clínica Camila Samara offers personalized treatments for the body and well-being in Brazil

Retrieved on: 
Sunday, December 24, 2023
Woman, Light-emitting diode, Drainage, Environment, Specialization, Skin care, Beauty, Cellulite, Groin, Pregnancy, Massage, Fibrosis, Female, Nursing

Her goal is to offer her clients the best aesthetic treatments, making them feel good about themselves and consequently raising their self-esteem.

Key Points: 
  • Her goal is to offer her clients the best aesthetic treatments, making them feel good about themselves and consequently raising their self-esteem.
  • Camila Samara offers services with cutting-edge technologies to provide customers with unique and personalized experiences.
  • Personalized service Camila Samara works from Monday to Saturday and on one day of the week she offers personalized service at home.
  • This way, I set aside one day a week to serve them “in the comfort of their homes, with more convenience,” said Camila Samara.